This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic agents (hormones that stimulate the bone marrow to make more red blood cells).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
89
Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
ferrous sulfate, 325 mg oral, three times daily for 6 weeks
Unnamed facility
Tucson, Arizona, United States
Unnamed facility
Los Angeles, California, United States
Change in Hemoglobin (Hgb)
Change from baseline to 7 weeks after 4 consecutive weekly Ferrlecit 250 mg intravenious infusion and change from baseline to 4 weeks after 6 weeks oral ferrous sulfate 325 mg tablets t.i.d.
Time frame: Baseline to 10 weeks
Change in Serum Ferritin
Change from baseline to 7 weeks after 4 consecutive weekly Ferrlecit 250 mg intravenious infusion and change from baseline to 4 weeks after 6 weeks oral ferrous sulfate 325 mg tablets t.i.d.
Time frame: Baseline to 10 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Unnamed facility
Palo Alto, California, United States
Unnamed facility
San Diego, California, United States
Unnamed facility
Hines, Illinois, United States
Unnamed facility
Indianapolis, Indiana, United States
Unnamed facility
Shreveport, Louisiana, United States
Unnamed facility
Baltimore, Maryland, United States
Unnamed facility
Springfield, Massachusetts, United States
Unnamed facility
Detroit, Michigan, United States
...and 14 more locations